Clinical Trials /

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

NCT02176902

Description:

This randomized phase II trial will evaluate if a low-fat diet with fish oil has the potential to delay disease progression in patients with prostate cancer undergoing active surveillance.

Related Conditions:
  • Prostate Adenocarcinoma
Recruiting Status:

Recruiting

Phase:

N/A

Trial Eligibility

Document

Title

  • Brief Title: Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
  • Official Title: A Phase II Randomized, Open-Label, Two-Arm Study of a Low-Fat Diet With Fish Oil Capsules vs. a Control Group in Men on Active Surveillance for Prostate Cancer

Clinical Trial IDs

  • ORG STUDY ID: 13-000432
  • SECONDARY ID: NCI-2014-01257
  • SECONDARY ID: 13-000432
  • SECONDARY ID: P30CA016042
  • SECONDARY ID: P50CA092131
  • NCT ID: NCT02176902

Conditions

  • Adenocarcinoma of the Prostate
  • Stage I Prostate Cancer
  • Stage IIA Prostate Cancer
  • Stage IIB Prostate Cancer

Purpose

This randomized phase II trial will evaluate if a low-fat diet with fish oil has the potential to delay disease progression in patients with prostate cancer undergoing active surveillance.

Detailed Description

      PRIMARY OBJECTIVES:

      I. Determine if a 1-year low-fat fish oil (omega-3 fatty acid) supplemented diet results in
      decreased prostate cancer Decipher score as compared to a control group in men on active
      surveillance.

      SECONDARY OBJECTIVES:

      I. Evaluate the effect of a low-fat (LF)/fish oil (FO) intervention on prostate biopsy tissue
      markers of progression, prostate biopsy pathologic features (Gleason grade, tumor volume ),
      prostate-specific antigen (PSA), and long-term clinical outcomes (clinical progression,
      prostate cancer therapies).

      II. Evaluate potential surrogate biomarkers of proliferation (red blood cell [RBC] membrane
      fatty acid analyses, ex-vivo bioassay).

      III. Determine if a correlation exists between free fatty acid receptor 4 (GPR120) levels and
      progression markers in response to the LF/FO intervention.

      IV. Evaluate effect of the intervention on the National Comprehension Cancer Network (NCCN)
      risk group V. Evaluate compliance with a 1-year + 2 year extension LF/FO intervention. VI.
      Evaluate safety of a 1-year + 2-year extension LF/FO intervention.

      OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive no intervention.

      ARM II: Patients receive dietary counseling with a research dietitian weekly for 1 month and
      then monthly for 11 months. Patients are given guidelines with recommended meals to follow a
      high omega-3, low omega-6 diet comprising 20% kilocalories (Kcal) from fat, 15% Kcal from
      protein, and 65% Kcal from carbohydrates for 1 year. Patients also receive 4 fish oil
      capsules per day orally (PO) for 1 year.

      After completion of study, patients are followed up yearly for 15 years.
    

Trial Arms

NameTypeDescriptionInterventions
Arm I (control)No InterventionPatients receive no intervention.
    Arm II (fish oil)ExperimentalPatients receive dietary counseling with research dietitian weekly for 1 month and then monthly for 11 months. Patients are given guidelines with recommended meals to follow a low-fat diet comprising 20% Kcal from fat, 15% Kcal from protein, and 65% Kcal from carbohydrates for 1 year. Patients also receive 4 fish oil capsules per day PO for 1 year.

      Eligibility Criteria

              Inclusion Criteria:
      
                -  Patients sign the informed consent
      
                -  Patient had a prostate biopsy performed by Dr. Mark with the Artemis device and has
                   adenocarcinoma of the prostate
      
                -  Patient elects to undergo active surveillance
      
                -  Clinical stage T2c or less
      
                -  Gleason grade 3+4 or less
      
                -  PSA < 20
      
                -  Geographically able to have study visits at the University of California, Los Angeles
                   (UCLA) Clinical Research Unit
      
                -  Subjects are willing to not consume lycopene, green tea or pomegranate supplements or
                   pomegranate juice during the 1-year study
      
                -  If subjects are randomized to the control group they agree to not consume fish oil
                   capsules during the 1-year study
      
              Exclusion Criteria:
      
                -  Diagnostic prostate biopsy with only 1 core with cancer and < 5% of tissue from that
                   core involved with cancer
      
                -  Patient has taken finasteride or dutasteride during the prior year
      
                -  Patient has taken fish oil during the prior 3 months
      
                -  Patient had prior treatment for prostate cancer (surgery, radiation, local ablative
                   therapy, anti-androgen therapy or androgen deprivation therapy)
      
                -  Patient has other medical conditions that exclude him from undergoing a repeat
                   prostate biopsy at 1-year
      
                -  Patient has allergy to fish
            
      Maximum Eligible Age:80 Years
      Minimum Eligible Age:50 Years
      Eligible Gender:Male
      Healthy Volunteers:No

      Primary Outcome Measures

      Measure:Decipher score in one year prostate biopsy tissue sample
      Time Frame:1 year
      Safety Issue:
      Description:The primary statistical analysis will be to compare the Decipher score between the two intervention arms using a two-sample t-test.

      Secondary Outcome Measures

      Measure:Composite measure: Prostate biopsy tissue markers of proliferation, cell cycle progression, and prostate biopsy pathologic features (Gleason grade, percent of cores with cancer, and percent of tissue with cancer)
      Time Frame:1 year
      Safety Issue:
      Description:Different types of regression models will be used to assess the influence of the intervention and clinical characteristics (ex. logistic regression, ordinal regression, Poisson regression instead of linear regression).
      Measure:Serum PSA
      Time Frame:Up to 1 year
      Safety Issue:
      Description:Different types of regression models will be used to assess the influence of the intervention and clinical characteristics (ex. logistic regression, ordinal regression, Poisson regression instead of linear regression).
      Measure:Composite measure: Long-term clinical outcomes (clinical progression, prostate cancer therapies)
      Time Frame:Up to 15 years
      Safety Issue:
      Description:Different types of regression models will be used to assess the influence of the intervention and clinical characteristics (ex. logistic regression, ordinal regression, Poisson regression instead of linear regression).
      Measure:Composite measure: Potential surrogate biomarkers of proliferation (RBC membrane fatty acid analyses, ex-vivo bioassay)
      Time Frame:Up to 1 year
      Safety Issue:
      Description:Different types of regression models will be used to assess the influence of the intervention and clinical characteristics (ex. logistic regression, ordinal regression, Poisson regression instead of linear regression). Whether the omega-6/omega-3 ratio provides additional predictive information beyond group will be assessed by investigating whether it correlates with Ki-67 within each group.
      Measure:Correlation of GPR120 expression in peripheral blood mononuclear cells (PBMCs) and prostate biopsy tissue with immunostaining of Ki67 and Decipher Score
      Time Frame:Up to 1 year
      Safety Issue:
      Description:Linear regression will be used to correlate PBMC and biopsy GPR120 gene and protein expression to 1-year Ki-67 index and Decipher score . GPR120 gene and protein expression will be added to the linear regression for Ki-67 constructed with group and clinical/demographic covariates.
      Measure:Compliance, defined as having taken 80% or more of the daily fish oil throughout the trial determined based on pill count
      Time Frame:Up to 1 year
      Safety Issue:
      Description:Analysis of subject compliance to dietary regimen
      Measure:Incidence of adverse events graded according to National Cancer Institute Common Toxicity Criteria version 4.0
      Time Frame:Up to 1 year
      Safety Issue:
      Description:Measure of adverse events incidence
      Measure:Sample storage for future research
      Time Frame:Up to 1 year
      Safety Issue:
      Description:Urine, plasma and flash frozen prostate tissue will be stored for future research evaluating the effects of a LF/FO diet on prostate cancer progression.

      Details

      Phase:N/A
      Primary Purpose:Interventional
      Overall Status:Recruiting
      Lead Sponsor:Jonsson Comprehensive Cancer Center

      Last Updated

      August 8, 2019